🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting News: Chris O’Brien Lifehouse has enrolled its first patient in the LMS Biomarker Clinical Study! The study focuses on patients with unresectable or metastatic leiomyosarcoma (LMS) undergoing first-line chemotherapy. Learn more about our research: sarcoma.org.au/projects #Research

On #International #Women and #Girls in #Science Day, we celebrate the outstanding contributions of women in our ANZSA community, advancing sarcoma cancer research. Today, we spotlight Jacqui McGovern, winner of the Choong Dickinson Best Poster Prize from our previous ASM!

IT'S TODAY! First Journal Club of 2025- Lead by Dr Andrew Johnston from New Zealand. Join us by signing up here: forms.office.com/Pages/Response…

ANZSA is offering two Sarcoma Research Grants with support from our generous donors to support Sarcoma Research. Two grants of up to $50,000 each are for direct research costs to improve both early detection and therapy for sarcoma! Apply here: sarcoma.org.au/pages/research…

The ReLaPSe Study is now open @petermaccancercentre! This international study being led by ANZSA aims to answer the question of which treatment option (surgery with or without preoperative radiotherapy) is best for patients diagnosed with recurrent retroperitoneal liposarcoma.

Reminder: Applications close - 5pm AEST Friday 2nd May 2025 for the ANZSA Sarcoma Research Grants. To learn more and apply visit our website: sarcoma.org.au/pages/research…

We're excited to announce that we’re now on #BlueSky 🚀 Join us there as we continue to connect and share sarcoma insights. 🔹 Search for us on BlueSky using Australia and New Zealand Sarcoma Association.bsky.social 🔹Find the link to ANZSA BlueSky account here: bsky.app/profile/anzsar…

🧬 Genetic Predisposition in Sarcoma Up to 20% #sarcoma may be assoc. with predisposition genes In our 📝 we review evidence on genetic predis. & how it may influence Rx decisions & management inc. surgery, radiotherapy, systemic Rx & surveillance 1/4 thelancet.com/journals/eclin…

TODAY! Please join us today for the second virtual ANZSA Sarcoma Journal Club of 2025. When: Wednesday, 30 April, 5pm - 6pm AEST Host: Dr. Susie Bae (Peter MacCallum Cancer Centre) Register here: forms.office.com/r/VLjFP39QPP

EP300::VGLL3 #rhabdomyosarcoma: a potential distinct indolent adult RMS subtype 🚨Think of this emerging subtype if: ✔️Male, aged 30-60 ✔️ Spindle cell / sclerosing #RMS 👅 of the tongue 🙌🏻 Appear indolent with good outcomes in all reported cases esmorarecancers.org/article/S3050-

Liz Connolly Australia and New Zealand Sarcoma Association Fiona Maclean Professor DM Thomas Tom Wei-Wu Chen Giacomo G Baldi Silvia Stacchiotti Inga-Marie Schaefer Jason L. Hornick, M.D., Ph.D. Paolo Dei Tos Tristan Rutland MBBS FRCPA IFCAP Liz Connolly take a look at our case of spindle cell rhabdomyosarcoma — with stunning images from the NotasDePatologia collection! This one features a more conventional paratesticular presentation in a 15-year-old adolescent. Best regards,

Join leading minds in sarcoma research and care at the 2025 ANZSA Annual Scientific Meeting, October 10–11 in Hobart. Connect with clinicians, researchers, and advocates to explore the latest in sarcoma science and multidisciplinary care. Register today: sarcoma.org.au/pages/2025-asm…

Abstract submissions are now open for the 2025 ANZSA Annual Scientific Meeting. We’re inviting poster submissions from all areas of sarcoma research! Deadline: Friday 1 August 2025 (midnight AEST) 📎 Follow the submission instructions at: aoa.org.au/events/cem-eve…

We’re pleased to announce that Winship Cancer Institute of Emory University in the US, is the second international site to join the ReLaPSe study - a prospective study evaluating standard treatment options for patients who’ve had a recurrence of a resected #retroperitoneal #liposarcoma.

Congratulations to Hayden Snow and David Gyorki on the publication of their latest paper in collaboration with the TARPSWG. A major step forward for improving outcomes for retroperitoneal sarcoma through international collaboration. Read here: journals.lww.com/annalsofsurger…

Peter Mac Cancer Centre has become first site in the world activated for a key stage of INTER-EWING-1 trial, a major global program improving outcomes for Ewing #Sarcoma - opening recruitment to Randomisations B1 and B2 to explore role of radiotherapy survival & recurrence risk😊

📢 The Provisional Program for the ANZSA Annual Scientific Meeting is now available. Take a look at the planned sessions and speakers, and don’t forget to register to attend. View the program here: sarcoma.org.au/pages/2025-asm…

Calling all researchers. Showcase your work at the 2025 ANZSA ASM and help shape the future of sarcoma care. Share your findings with a multidisciplinary audience committed to innovation. Abstract submissions are now open- Don't miss out! Submit here: sarcoma.org.au/pages/2025-asm…